Thomas Wilder Sells 360 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 360 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $264.58, for a total value of $95,248.80. Following the transaction, the director now directly owns 4,533 shares in the company, valued at approximately $1,199,341.14. This trade represents a 7.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Thomas Wilder also recently made the following trade(s):

• On Wednesday, April 2nd, Thomas Wilder sold 360 shares of Penumbra stock. The stock was sold at an average price of $266.93, for a total value of $96,094.80.

Penumbra Price Performance

NYSE PEN opened at $262.37 on Friday. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The company has a market cap of $10.11 billion, a PE ratio of 771.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The firm’s 50-day simple moving average is $274.48 and its two-hundred day simple moving average is $245.21.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. Research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on PEN shares. Robert W. Baird increased their price objective on Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. UBS Group upped their target price on shares of Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. raised their price target on shares of Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Citigroup boosted their price target on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Finally, Truist Financial lifted their target price on shares of Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $294.47.

Hedge Funds Weigh In On Penumbra

Large investors have recently made changes to their positions in the stock. State Street Corp raised its stake in shares of Penumbra by 0.3% during the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after purchasing an additional 3,863 shares during the period. RTW Investments LP grew its holdings in Penumbra by 8.4% during the 4th quarter. RTW Investments LP now owns 862,450 shares of the company’s stock valued at $204,815,000 after buying an additional 66,700 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Penumbra by 23.4% during the fourth quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock valued at $173,416,000 after buying an additional 138,387 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Penumbra by 47.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company’s stock worth $167,913,000 after buying an additional 227,506 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Penumbra by 128.1% in the third quarter. Janus Henderson Group PLC now owns 668,873 shares of the company’s stock valued at $129,967,000 after acquiring an additional 375,684 shares during the period. 88.88% of the stock is owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.